Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. Antibody–drug conjugates are an example of bioconjugates and immunoconjugates. ADCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue.

In the present book, thirteen typical literatures about Antibody–drug conjugates published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on Antibody–drug conjugates. We hope this book can demonstrate advances in Antibody–drug conjugates as well as give references to the researchers, students and other related people.